icolung is a cloud-based AI software to quantify the degree of lung involvement in COVID-19 patients. CE cleared, in the US available for clinical use during public health emergency related to COVID-19.

icolung provides the quantification of lung pathology in COVID-19 patients.
- Automated quantification
- Assessment of lesion burden
- Total and regional volumetrics in 6 pulmonary regions
- Quantification per type of CT finding (e.g. GGO, …)
Information source: Vendor
Last updated: June 18, 2020

General Information

Product name icolung
Company icometrix
Subspeciality Chest
Modality CT
Disease targeted COVID-19
Key-features Quantification of lung involvement, total and lobular, lesion classification
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), report suggestion

Technical Specifications

Data characteristics
Population All non-contrast chest CT images
Input non-contrast chest CT image
Input format DICOM
Output Color-coded segmentation overlays, report with quantification of lung involvement.
Output format DICOM
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform
Deployment Cloud-based
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 1 - 10 minutes


Certified, Class I , MDD
FDA No or not yet
Intended Use Statements
Intended use (according to CE) icobrain ct is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of computed tomography (CT) images. This software is intended to automate the current manual process of identifying, labeling and quantifying the volume of segmentable brain structures identified on CT images. The software can also be used to perform image processing, analysis, and communication of computed tomography perfusion (CTP) scans of the brain.


Market presence
On market since 04-2020
Distribution channels Siemens Teamplay, Calantic
Countries present (clinical, non-research use) 17
Paying clinical customers (institutes) 75
Research/test users (institutes) 20
Pricing model Pro bono
Based on Public need


Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers https://icometrix.com/resources/the-role-of-imaging-ai--and--ct-in-covid19